WO1993003058A3 - Non-desensitizing analogs of gnrh and other biologically active ligands - Google Patents

Non-desensitizing analogs of gnrh and other biologically active ligands Download PDF

Info

Publication number
WO1993003058A3
WO1993003058A3 PCT/CA1992/000281 CA9200281W WO9303058A3 WO 1993003058 A3 WO1993003058 A3 WO 1993003058A3 CA 9200281 W CA9200281 W CA 9200281W WO 9303058 A3 WO9303058 A3 WO 9303058A3
Authority
WO
WIPO (PCT)
Prior art keywords
desensitizing
analogs
membered ring
biologically active
gnrh
Prior art date
Application number
PCT/CA1992/000281
Other languages
French (fr)
Other versions
WO1993003058A2 (en
Inventor
Graham J Moore
Hamid R Habibi
John M Matsoukas
Original Assignee
Univ Technologies Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Technologies Int filed Critical Univ Technologies Int
Priority to EP92914041A priority Critical patent/EP0592512A1/en
Priority to JP5501722A priority patent/JPH06509075A/en
Publication of WO1993003058A2 publication Critical patent/WO1993003058A2/en
Publication of WO1993003058A3 publication Critical patent/WO1993003058A3/en
Priority to NO934887A priority patent/NO934887L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to novel non-desensitizing analogs of a biologically active ligand having at least one 6-membered ring or 5-membered ring and a method for selecting non-desensitizing analogs of a biologically active ligand having at least one 6-membered ring or 5-membered ring. Additionally, the present invention is directed to a novel method for treating a patient in a non-desensitizing fashion with a non-desensitizing analog of a biologically active ligand having at least one 6-membered ring or 5-membered ring. Moreover, the present invention is directed to a novel method for making new and useful non-desensitizing analogs of GnRH and opiate peptides as well as the novel non-desensitizing compounds and compositions prepared thereby.
PCT/CA1992/000281 1991-07-01 1992-07-02 NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS WO1993003058A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP92914041A EP0592512A1 (en) 1991-07-01 1992-07-02 NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
JP5501722A JPH06509075A (en) 1991-07-01 1992-07-02 Desensitizing Analogs of GnRH and Other Biologically Active Ligands
NO934887A NO934887L (en) 1991-07-01 1993-12-29 Non-desensitizing analogs of GnRH and other biologically active ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72132491A 1991-07-01 1991-07-01
US721,324 1991-07-01

Publications (2)

Publication Number Publication Date
WO1993003058A2 WO1993003058A2 (en) 1993-02-18
WO1993003058A3 true WO1993003058A3 (en) 1993-05-27

Family

ID=24897506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1992/000281 WO1993003058A2 (en) 1991-07-01 1992-07-02 NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS

Country Status (4)

Country Link
EP (1) EP0592512A1 (en)
JP (1) JPH06509075A (en)
CA (1) CA2112566A1 (en)
WO (1) WO1993003058A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9100468D0 (en) * 1991-01-09 1991-02-20 Proteus Molecular Design Improvements in and relating to hormones
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5677184A (en) * 1994-04-19 1997-10-14 Takeda Chemical Industries, Ltd. CHO cells that express human LH-RH receptor
BR9908619A (en) 1998-03-05 2001-10-02 Agouron Pharma Compound and its production process, pharmaceutical composition, and method to regulate the secretion of gonadotropins in mammals
DE69924387D1 (en) 1998-08-20 2005-04-28 Agouron Pharma NON-PEPTIDIC GNRH AGENTIA, METHOD AND INTERMEDIATE CONNECTIONS FOR THE PRODUCTION THEREOF
WO2002072602A2 (en) 2001-03-08 2002-09-19 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CA2489252A1 (en) 2002-06-13 2003-12-24 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985001292A1 (en) * 1983-09-19 1985-03-28 Victor Brantl Pharmacologically active peptides
EP0413209A1 (en) * 1989-08-07 1991-02-20 TAP Pharmaceuticals Inc. LHRH analogs
WO1991010140A2 (en) * 1989-12-29 1991-07-11 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985001292A1 (en) * 1983-09-19 1985-03-28 Victor Brantl Pharmacologically active peptides
EP0413209A1 (en) * 1989-08-07 1991-02-20 TAP Pharmaceuticals Inc. LHRH analogs
WO1991010140A2 (en) * 1989-12-29 1991-07-11 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A.F.SPATOLA , EDITOR: B.WEINSTEIN 'CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS' 1983 , MARCEL DEKKER, INC. , NEW YORK *
CAN.J.PHYS.PHARM. vol. 63, no. 8, August 1985, pages 966 - 971 G.J.MOORE 'STRUCTURE-DESENTISIATION RELATIONSHIPS OF ANGIOTENSIN ANALOGUES IN THE RAT ISOLATED UTERUS' *
CHEMICAL ABSTRACTS, vol. 106, no. 25, 22 June 1987, Columbus, Ohio, US; abstract no. 207987, A.PHILIPS 'Sensitivity differences in reproductive/endocrine organs to chronically administered LHRH agonists in female rats' page 95 ;column 1 ; *
J.CHEM.EDUCATION vol. 66, no. 2, February 1989, pages 111 - 117 S.CHEATHAM 'NMR SPECTROSCOPY IN BIOCHEMISTRY' *
KLEOMENIS BARLOS, ET AL.: "2-CHLOROTRITYL CHLORIDE RESIN. \STUDIES ON ANCHORING OF FMOC-AMINO ACIDS AND PEPTIDE CLEAVAGE.", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH., MUNKSGAARD, COPENHAGEN., DK, vol. 37., no. 06., 1 June 1991 (1991-06-01), DK, pages 513 - 520., XP000206367, ISSN: 0367-8377 *
'THE MERCK INDEX' 1989 , MERCK & CO , RAHWAY *

Also Published As

Publication number Publication date
EP0592512A1 (en) 1994-04-20
JPH06509075A (en) 1994-10-13
WO1993003058A2 (en) 1993-02-18
CA2112566A1 (en) 1993-02-18

Similar Documents

Publication Publication Date Title
WO1993003058A3 (en) Non-desensitizing analogs of gnrh and other biologically active ligands
EP0787009A4 (en) Cancer inhibitory peptides
GR3006718T3 (en)
CA2029678A1 (en) Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 14
AU3884589A (en) Intravenous pharmaceutical composition comprising cyclosporins
HU9600281D0 (en) Therapeutic peptide derivatives
ATE105482T1 (en) TREATMENT OF CANCER WITH SOMATOSTATIN AND ANALOGS THEREOF.
AU1843297A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
GR3032611T3 (en) Imidazoquinoxalinones, their aza analogs and process for their preparation.
DK0482013T3 (en) Non-glycolysed human interleukin-3 analog proteins
EP0273534A3 (en) Oxa(thia)diazole derivatives
DE69723728D1 (en) TOTAL SYNTHESIS OF THE AMINO HIP ANALOG OF DIDEMNIN A
KR880011198A (en) Cyclic Peptides and Methods for Making the Same
EP0339549A3 (en) Tyr-peptide analogs
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
EP0328090A3 (en) Lhrh analogs
EP0366041A3 (en) Imido-percarboxylic acids
ES8506016A1 (en) New pharmacologically active pyrazolopyridines.
DE69418353D1 (en) Cyclic pentapeptides with beta-turn and gamma-turn
AU624733B2 (en) Naphthalene and tetrahydronaphthalene substituted gem- diphosphonate compounds and their use in therapy
EP0351795A3 (en) Novel deoxyadenosine compounds and methods of making and using the same
EP0235904A3 (en) Treatment of allergy with thymopentin
AU3617489A (en) A peptide with antihypertensive activity
LV10289B (en) New pentapeptide and a process for the preparation thereof
EP0154544A3 (en) Des-proline vasopressin antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP NO RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP NO RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 2112566

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992914041

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992914041

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992914041

Country of ref document: EP